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Imidazoquinolines are synthetic toll-like receptor 7 and 8 agonists and potent dendritic cell activators with established
anticancer activity. Here we test the hypothesis that imidazoquinoline has in vivo eﬃcacy within established renal cell
carcinoma (RCC) tumors. Immunocompetent mice bearing syngeneic RCC xenografts were treated with imidazoquinoline
or placebo at two separate time points. Harvested tumors were assayed by TUNEL/caspase-3/Ki67 immunostains to evaluate
cell death/apoptosis/proliferation, and CD3/B220/CD45 immunostains to evaluate T-cell lymphocyte/B-cell lymphocyte/pan-
leukocyte tumor inﬁltration. ELISA measurement of tumor and serum levels of proinﬂammatory cytokines, IL-6 and MCP-1, was
performed. A single imidazoquinoline dose signiﬁcantly decreased RCC tumor growth by 50% and repeat dosing compounded
the eﬀect, without observed weight loss or other toxicity. Tumor immunostaining revealed signiﬁcant increases in cell death and
apoptosis without changes in cell proliferation, supporting induction of apoptosis as the primary mechanism of tumor growth
suppression. Imidazoquinoline treatment also signiﬁcantly enhanced peritumoral aggregation and intratumoral inﬁltration
by T-cell lymphocytes, while increasing intratumoral (but not serum) levels of proinﬂammatory cytokines. In conclusion,
imidazoquinolinetreatmentenhancesT-celllymphocyteinﬁltrationandproinﬂammatorycytokineproductionwithinestablished
mouse RCC tumors, while suppressing tumor growth via induction of cancer cell apoptosis. These ﬁndings support a therapeutic
role for imidazoquinoline in RCC.
1.Introduction
Kidney cancer is responsible annually for over 58,000 new
diagnoses and 13,000 deaths in the US [1]. Approximately
85%ofthesecancersarerenalcellcarcinomas(RCCs)arising
from the renal tubule epithelial lining. RCC includes distinct
histologic subtypes deﬁned by diﬀerent clinical behaviors,
the most common being clear cell (65%), papillary (15%),
and chromophobe RCC (5%). Despite earlier stage of detec-
tion in recent decades, RCC patient mortality has not
decreased accordingly, and recurrence following deﬁnitive
local therapy by surgery or ablative techniques remains a
signiﬁcant clinical challenge [2]. For patients presenting or
recurring with RCC metastases, prognosis is poor, with a
5-year survival of less than 10% [3]. While multityrosine
kinase inhibitors have shown recent promise with frequent
clinicalresponses,completerespondersarelacking,andthere
is question regarding survival beneﬁts and durability of
response [4, 5].
Interest in immunotherapy for RCC patients was ignited
four decades back with the suggestion that immune cell
activation mediates the occasional spontaneous regression
of RCC pulmonary metastases [6]. The concept that the
immune system may mediate RCC tumor suppression2 Journal of Oncology
has gained more recent support from clinical success of
immunotherapies in treating patients with metastatic RCC.
To date, IFN-alpha and IL-2 remain among the most
successful treatments for metastatic clear cell RCC, with
modest survival beneﬁts in prospective randomized trials
and an approximately 5% incidence of durable complete
response [7, 8]. The more recent demonstration of cancer-
speciﬁc antigens recognized by T-cell lymphocytes found in
RCC patient tumors has further supported the role of the
immune system in this disease [9].
Relative to other solid tumor cancers, RCC tumors are
highly immunogenic, as evidenced by abundant cytotoxic
T-cell lymphocyte inﬁltrates showing speciﬁcity for autolo-
gous RCC cells [9, 10]. Despite their immunogenicity, the
plasticity of RCC tumors enables them to escape immune
destruction by what is increasingly believed to involve a
variety of escape mechanisms [11]. Speciﬁc defects in T-
cell lymphocytes from RCC patients have been identiﬁed
and include dysregulated signaling pathways and increased
apoptotic tendency [12] .C e n t r a lt ot h i si m m u n eb r e a k d o w n
may be the ability of some immunogenic tumors to block
activation of dendritic cells, the primary antigen-presenting
cells responsible for downstream eﬀector T-cell lymphocyte
activation [13]. Targeting dendritic cell activation may
therefore provide an eﬀective therapeutic strategy for clinical
RCC.
Imidazoquinolines are synthetic immunomodulatory
drugs that act by binding toll-like receptors 7 and 8
(TLR7/TLR8) on dendritic cells, structurally mimicking
these receptors’ natural ligand, viral single-stranded RNA
[14, 15]. Whereas TLR8 is expressed in humans, only
T L R 7i se x p r e s s e di nb o t hh u m a n sa n dm i c e .A c t i v a t i o no f
TLR7inducesdendriticmaturationthroughtheMyD88/NF-
kappaB signaling pathway, enhancing antigen presentation
and downstream activation of antigen-speciﬁc T-cells, with
profound elaboration of proinﬂammatory cytokines and
chemokines including IFN-alpha, IL-6, IL-12, TNF-alpha,
and MCP-1/CCL2 [15–19]. The net result is a coordinated
immune response with potent antiviral and antitumor
eﬀects [13]. The best characterized imidazoquinoline to
date, imiquimod, has demonstrated clinical eﬃcacy against
human papilloma virus/genital condyloma, basal cell carci-
noma, and actinic keratosis and is approved by the Food
and Drug Administration for topical treatment of these
diseases. Additionally, there is a growing body of clinical
evidence that imiquimod is eﬀective in the treatment of
other dermatologic malignancies, including melanoma and
squamous cell carcinoma, with complete responses reported
[20–22].
We have previously demonstrated a novel imidazoquino-
line, 3M011, has in vivo eﬃcacy against bladder tumori-
g e n e s i sa sw e l la ss y s t e m i c a l l yd i s s e m i n a t e dR C Cc e l l si na
metastatic mouse model [23, 24]. However, imidazoquino-
line activity in established primary RCC tumors and its
eﬀects on lymphocyte inﬁltration or cytokine production
in this cancer type have not yet been explored. Here, we
employ a syngeneic xenograft mouse model to test the
hypothesis that imidazoquinoline therapy has in vivo eﬃcacy
inestablishedRCCprimarytumorswithregardtoanticancer
activity, lymphocytic inﬁltration, and intratumoral proin-
ﬂammatory cytokine production.
2.MaterialsandMethods
2.1. Cell Line. Experiments were performed using the kidney
cancer cell line, RENCA, which was originally derived from
a spontaneous RCC tumor in the BALB/c mouse strain.
Cells were grown in vitro in RPMI media supplemented with
L-glutamine (2mM), penicillin (100U/mL), streptomycin
(100U/mL), and 10% fetal bovine serum. Cell cultures were
maintained at 37◦C and 5% CO2.
2.2. Mouse Model and Treatments. Syngeneic RCC primary
tumor xenografts were generated by injection of 2 × 105
RENCA cells subcutaneously in the left ﬂank of N = 28
eight-week-old female Balb/c mice (Jackson Laboratory, Bar
Harbor, ME), giving rise to palpable tumors by two weeks
after injection. Mice were randomized at 17 days after
inoculation (deﬁned as Day 0) to treatment by intratumoral
injection with 0.1mL of either 0.5mg/mL (∼2.5mg/kg)
3M011 imidazoquinoline (3M Pharmaceuticals, St. Paul,
MN) or placebo control (sodium citrate vehicle, 0.03M, pH
6.0). One week after initial treatment (Day 7), mice were
rerandomized to receive either 3M011 or placebo injection.
Four treatment arms were thus generated based on day 0/day
7t r e a t m e n t s( Figure 1). Mouse weights and tumor volumes
were measured every 1-2 days, with volumes calculated as
0.4 × (width)2× (length). Mice were sacriﬁced on day 9,
and tumor weights were compared among treatment groups.
Tumors and serum were harvested for immunohistochem-
istry and ELISA assays described below.
2.3. ELISA. P r o t e i ne x t r a c tf r o mh a r v e s t e dm o u s et u m o r s
was obtained by mechanical homogenization of 100mg
tumor in 500μL of PBS supplemented with 1mM protease
inhibitor phenylmethylsulfonyl ﬂuoride (PMSF) and a mild
detergent (Triton X-100, 0.05%). Tumor protein extract
and mouse serum were assayed by ELISA for levels of
IL-6 and MCP-1 (Biolegend, San Deigo, CA). Brieﬂy, 96-
well plates were coated overnight with anti-mouse IL-6 or
MCP-1 capture antibody at 4◦C. Serum or tumor extract
supernatant were added to wells after 1:5–1:20 dilution,
followed by successive incubations at room temperature
with anti-mouse IL-6 or MCP-1 detection antibody and
horse radish peroxidase-conjugated anti-mouse secondary
antibody. Color reactions were generated with the addition
of peroxidase substrate and terminated after 15 minutes with
2NH 2SO4.Absorbanceat450nmwavelengthwasmeasured,
and protein concentration was determined by interpolation
onto absorbance curves generated by recombinant IL-6 and
MCP-1 protein standards.
2.4. Tumor Immunohistochemistry. Following tissue removal
for ELISA, the remaining harvested tumor tissue was
ﬁxed in 10% formalin solution, embedded in paraﬃn,
and sectioned for immunohistochemical staining. Sections
were heat deparaﬃnized at 58–60◦C for 30 minutes. For
TUNEL (Terminal deoxynucleotidyl transferase-mediatedJournal of Oncology 3
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Figure 1: Generation of four mouse treatment groups. N = 28 mice harboring RENCA RCC tumor xenografts were randomized on day 0
and again on day 7 to treatment with either 3M011 imidazoquinoline or placebo. Four treatment groups (N = 7) were thus generated based
on day 0/day 7 treatments: (I) 3M011/3M011, (II) 3M011/placebo, (III) placebo/3M011, and (IV) placebo/placebo.
dUTP Nick End Labeling) staining identiﬁcation of non-
viable cells, antigen retrieval was performed by 15-minute
incubation with 20μg/mL proteinase K (Sigma, St. Louis,
MO) in 10mM TRIS-HCl, pH 8.0, followed by endogenous
peroxidase quenching with 3% hydrogen peroxide in PBS.
TUNEL staining was then performed for one hour at 37◦C
with 2.0 units/μL terminal transferase (Roche, Indianapolis,
IN), 0.2nmol biotin-16-dUTP (Roche, Indianapolis, IN),
2.5mM cobalt chloride (Roche, Indianapolis, IN), 0.1M
sodium cacodylate pH 7.0 (Sigma, St. Louis, MO), 0.1mM
DTT (Sigma, St. Louis, MO), and 0.05mg/mL bovine
serum albumin (Sigma, St. Louis, MO). All other antigen
retrieval was performed by microwaving at high power
in 10mM sodium citrate buﬀer (Sigma, St. Louis, MO),
with the exception of B220 immunostaining, for which no
antigen retrieval step was performed. After antigen retrieval,
tumor sections were preincubated in 10% goat serum (MP
Biomedicals) for 30 minutes at room temperature followed
by primary antibody dilution in 2% bovine serum albumin
overnight at 4◦C. Speciﬁc primary antibodies and dilutions
included goat anticleaved caspase 3 (Cell Signaling Cat.
no. 9661) at 1:250 dilution (apoptotic cell identiﬁcation);
goat anti-Ki67 (Vector Laboratories Cat. no. VP-K451) at
1:10,000 dilution (cell proliferation identiﬁcation); rabbit
anti-CD3 (Dako Cat. no. A0452) at 1:1000 dilution (T-cell
lymphocyte identiﬁcation); rat anti-B220 (BD Pharmingen
Cat. no. 550286) at 1:200 dilution (B-cell lymphocyte
identiﬁcation); rat anti-CD45 (BD Pharmingen Cat. no.
550539) at 1:10 dilution (pan-leukocyte identiﬁcation).
Sections were then incubated with secondary antibody for 30
minutes at room temperature, using biotinylated goat anti-
rabbit IgG (Vector Labs BA-1000) at 1:1000 dilution for
cleavedcaspase-3,Ki67,andCD3,orbiotinylatedrabbitanti-
rat IgG (Vector Labs BA-4001) at 1:100 dilution for CD45
and B220. For color stain reaction, sections were incubated
with Vectastain Avidin-Biotin Complex Elite (Vector Labs)
diluted 1:25 in PBS for 30 minutes, followed by 3,3-
diaminobenzidine (Sigma, St. Louis, MO) and hematoxylin
counterstain. Appropriate positive and negative control
tissues(e.g.,mousespleen,mouselymphnodes)werestained
simultaneously. For all nonleukocytic markers, tumor stains
were scored as the percentage of positively staining tissue.
For leukocyte markers (CD3, CD45, and B220), the tumors
were scored 0+ to 4+ separately for (1) peritumoral/capsular
staining and (2) intratumoral staining. A maximum score
(4+) for peritumoral (capsular) staining was given for
leukocyte staining at least several cell layers thick and diﬀuse
around the entire tumor edge. A maximum score (4+) for
intratumoral staining was given for inﬁltrating leukocytes
detectable within the tumor at close to a 1:1 ratio with
surrounding cancer cells.
2.5. Statistical Analysis. Statistical comparisons of mean
valueswereperformedusingaStudent’sT-test.OnlyP values
< 0.05 were considered signiﬁcant.
3. Results
3.1. Imidazoquinoline Eﬀect on RCC Tumor Growth. Mice
harboring syngeneic RCC primary tumor xenografts (N =
28) were treated on day 0/day 7 with imidazoquino-
line/imidazoquinoline (N = 7), imidazoquinoline/placebo
(N = 7), placebo/imidazoquinoline (N = 7), or
placebo/placebo (N = 7) (Figure 1). Imidazoquinoline
treatment was well tolerated with no episodes of shivering,
tremors,orraisedfur.Miceremainedactivewithweightswell
maintained following both initial and repeat dosing (Figures
2(a) and 2(b)).4 Journal of Oncology
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Figure 2: Intratumoral 3M011 injection does not alter mouse weight. (a) Mean percent change in mouse weight following 3M011 versus
placebo treatment on day 0 (P = 0.47, 0.14, and 0.82 at 2, 4, and 7 days, resp.). (b) Mean percent change in mouse weight following 3M011
versus placebo treatment on day 7 (P = 0.13). Error bars = standard error of the mean.
Mean tumor size at initial treatment was 0.13cm3,
with no signiﬁcant diﬀerence between imidazoquinoline
and placebo arms. As shown in Figure 3, a single dose
of imidazoquinoline on day 0 signiﬁcantly decreased RCC
tumor growth rate over the following week relative to
placebo,yieldingarelative ∼50%r eductionintumorv olume
at all subsequently measured time points (Figure 3(a)).
Delaying the ﬁrst dose of imidazoquinoline until day 7,
when tumors were on average >600% larger, still resulted in
signiﬁcantinhibitionoftumorgrowth,causingpartialtumor
regressionoverthefollowing48hoursdespitea32%increase
in placebo-treated tumor size (P<0.01) (Figure 3(b)).
Mice receiving their second dose of imidazoquinoline on
day 7 showed a continued response, with no tumor growth
over the following 48 hours despite 46% enlargement of
control tumors (P<0.005) (Figure 3(c)). Weights of tumors
h a r v e s t e do nd a y9w e r e5 0 %l o w e ri nm i c et r e a t e do nd a y0
with imidazoquinoline compared to those receiving placebo
(P<0.001) (Figure 3(d)).
3.2. Imidazoquinoline Eﬀect on RCC Tumor Cell Death and
Proliferation. TUNEL staining was used to assess the degree
o fc e l ld e a t hi nt r e a t e dm o u s et u m o r sa san o n s p e c i ﬁ c
marker of necrosis and apoptosis. Mouse tumors had
variable TUNEL positivity, ranging from 10% to 80% of the
sectionedtissueareas,reﬂectingwhatappearedhistologically
as patchy regions of tumor necrosis (Figures 4(a) and
4(b)). However, TUNEL positivity was on average signiﬁ-
cantly more frequent in mice treated with imidazoquinoline
compared to placebo (Figure 4(g)). Furthermore, only in
imidazoquinoline-treated tumors did tissue regions corre-
sponding to TUNEL positivity also demonstrate frequent
positive staining for cleaved caspase-3 indicative of apoptosis
(Figures 4(c)–4(f),a n d4(h)). Speciﬁcally, the percentage of
tumor tissue with positive cleaved caspase-3 staining was on
average 26% in imidazoquinoline-treated tumors compared
to just 4% in placebo-treated tumors (P<0.001). No
signiﬁcant diﬀerence in cell proliferation based on Ki67
staining was observed in imidazoquinoline versus placebo-
treated tumors (Figure 5).
3.3. Imidazoquinoline Eﬀect on Intratumoral Leukocytic Inﬁl-
tration. To evaluate the eﬀect of the imidazoquinoline treat-
ment on leukocytic inﬁltration, mouse tumors were stained
for immune cell protein markers CD3 (T-cell lymphocyte
marker), B220 (B-cell lymphocyte marker), and CD-45
(pan-leukocyte marker) 2 days and 9 days after mouse
treatment.Inmicereceivingplacebotreatmentsonly,tumors
demonstrated mild-to-moderate (1-2+) T-cell lymphocytic
inﬁltration by CD3 staining, mostly conﬁned around the
tumor edge with only sparse penetration into the central
tumor (Figures 6(a)–6(c)). In contrast, with one excep-
tion, all mice receiving two imidazoquinoline treatments
demonstrated large (3-4+) peritumoral aggregates of T-
c e l ll y m p h o c y t e sa sw e l la sd i ﬀuse (3-4+) inﬁltration into
the central tumor (Figures 6(d)–6(h)). The one exception
occurred in a tumor with only mild-to-moderate (1-2+) T-
cell lymphocytic inﬁltration despite two imidazoquinoline
treatments; notably, this one tumor was of large size and
had minimal (<5% of tumor) apoptosis by cleaved caspase-
3 staining, suggesting resistance to imidazoquinoline. Mice
treated only once with imidazoquinoline also had increased
T-cell lymphocytic inﬁltration relative to placebo-treated
mice, but not to the extent as mice receiving two imidazo-
quinoline treatments (Figures 6(g) and 6(h)). Staining for
the CD45 pan-leukocyte marker in all tumors correlatedJournal of Oncology 5
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Figure 3: 3M011 reduces RCC tumor growth in mice. RENCA RCC xenografts in mice (N = 28) were treated on day 0 and day 7 with
3M011 imidazoquinoline or placebo. (a) Tumor growth following 3M011 versus placebo treatment on day 0. (b) Tumor growth following
retreatment with 3M011 versus placebo on day 7 in mice receiving placebo on day 0. (c) Tumor growth following retreatment with 3M011
versus placebo on day 7 in mice receiving 3M011 on day 0. (d) Mean weights of tumors harvested on day 9 based on day 0/day 7 treatment.
∗P<0.001; ∗∗P<0.01; ∗∗∗P<0.05; ∗∗∗∗P<0.10; ‡P = 0.45; error bars = standard error of the mean.
closely with CD3 staining (data not shown), supporting
that T-cell lymphocytes constitute the primary bulk of
RENCA tumor inﬁltrating leukocytes. B220 staining picked
up only rare scattered single cells without diﬀerences in
imidazoquinoline-treated and placebo-treated tumors (data
not shown), supporting the relative lack of B-cell lympho-
cytic inﬁltration in RCC tumors and the imidazoquinoline-
mediated immune response.
3.4.ImidazoquinolineEﬀectonI ntr atumor alC yto kineP r oduc-
tion. Serum and tumor levels of proinﬂammatory cytokines,
IL-6 and MCP-1, were assessed by ELISA 2 days and/or 9
days after treatment with imidazoquinoline. In tumor tissue,
high levels of IL-6 (>3000pg/100mg tumor) were observed
exclusively in imidazoquinoline-treated tumors, which on
average had four times higher levels than placebo-treated
tumors (P<0.01) (Figures7(a)and7(b)).Similarly, levelsof
MCP-1 were on average nearly double in imidazoquinoline-
treatedtumorscomparedtocontrols(P<0.01)(Figures7(c)
and7(d)).Micereceivingtwodoses ofimidazoquinoline had
nearly double the IL-6 levels of single-dosed mice; however,
this diﬀerence was not statistically signiﬁcant (P = 0.26).
Similarly, no signiﬁcant diﬀerences in intratumoral MCP-
1 levels were observed between once and twice dosing of6 Journal of Oncology
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Figure 4: 3M011 increases cell death in mouse RCC tumors. (a), (b) Representative example of a positive TUNEL patch of tissue at 100x (a)
and 200x (b) magniﬁcation in a tumor treated 2 days prior with 3M011 imidazoquinoline; patchy tissue TUNEL positivity was also observed
in placebo-treated tumors (not pictured). (c), (d) Representative example of negative cleaved caspase-3 immunostain at 200x (c) and 400x
(d) magniﬁcation in a placebo-treated tumor, including a tissue patch with corresponding TUNEL positivity (bottom two-thirds of each
picture). (e), (f) Representative example of diﬀusely positive cleaved caspase-3 immunostain at 200x (e) and 400x (f) magniﬁcation in a
large tissue region corresponding to TUNEL positivity from a 3M011-treated tumor. (g), (h) Mean percentage of tissue staining positive for
TUNEL (g) and cleaved caspase-3 (h) among tumors treated 2 days prior with placebo versus 3M011. ∗P<0.05; ∗∗P<0.001; error bars =
standard error of the mean.
imidazoquinoline (Figure 7(c)). In mouse serum, no dif-
ferences in MCP-1 levels were observed following imida-
zoquinoline treatments compared to controls, (Figures 7(e)
and 7(f)) and serum IL-6 remained undetectable below our
ELISA assay limit of >30pg/mL in all mice regardless of
treatment.
4. Discussion
Despite the existence of tumor-speciﬁc antigens recognizable
by the host immune system, the ability of diﬀerent cancers to
e v o k ea ni m m u n er e s p o n s ei sq u i t ev a r i a b l e ,w i t hm o s ts o l i d
tumors being only weakly immunogenic [9, 10]. In contrast,Journal of Oncology 7
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Figure 5: 3M011 does not aﬀect RCC tumor cellular proliferation. (a), (b) Immunohistochemical staining of RENCA RCC xenografts for
Ki-67 cell proliferation marker following treatment 2 days prior with placebo (a) or 3M011 imidazoquinoline (b), representative examples at
100x magniﬁcation. (c) Mean percentage of tumor tissuewith positive Ki67 staining 2 days after placebo versus 3M011 treatment. ‡P = 0.21.
RCCsolidtumorsarehighlyimmunogenicwithabundantT-
cell lymphocytic inﬁltration, and immunotherapies such as
IL-2 and IFN-alpha are among the most successful systemic
treatments for RCC patients [7, 8]. However, only a minority
of metastatic RCC patients respond to these treatments,
and primary tumors are particularly resistant, suggestive of
underlying RCC immunoevasion.
Dendritic cell inactivation may play a central role
in cancer immunoevasion. Maturation of dendritic cells
initiated by TLR7 activation is a well-known requisite for
downstream activation of antigen-speciﬁc T-cell eﬀector
responses [13]. High levels of immature dendritic cells
have been demonstrated in cancer patients and shown to
cause T-cell unresponsiveness in animal tumor models [25–
28]. In RCC primary tumors, immature dendritic cells
may accumulate as a result of upregulated immunoevasive
antigensonRCCcells,suchastheB7familyofPD-1receptor
ligands (e.g., B7-H1) or immunosuppressive cytokines such
as IL-10 [29, 30]. Therapeutic targeting of dendritic cell
activation in RCC patients may thus provide a novel strategy
for countering immunoevasion in both primary tumors and
systemically disseminated disease.
Imidazoquinolines are synthetic TLR7/TLR8 agonists
and potent dendritic cell activators with established anti-
cancer activity in both patients and mice [23, 31]. The
prototypical agent, imiquimod, has had clinical success in
the topical treatment of dermatologic malignancies [20–22].
In addition, we have previously described in vivo eﬃcacy of
therelatedimidazoquinoline, 3M011,insuppressingbladder
cancer tumorigenicity and RCC pulmonary colonization in
a metastatic mouse model [23, 24]. In our current study,
we have employed a syngeneic primary tumor xenograft
mousemodeltoshowthat3M011alsohasinvivosuppressive
activity against established RCC tumors. Speciﬁcally, 3M011
intratumoral injection decreased mouse RCC tumor size by
approximately 50% relative to placebo controls. This growth
inhibition was apparent after two days following a single
dose, and repeat dosing one week later compounded the
eﬀect. Growth inhibition was independent of pretreatment
tumor size, as initial treatment of even large tumors (∼5%
of the mouse total body mass) still resulted in partial tumor
regression. The durability of tumor responses with repeat
dosing observed in this study is in contrast to the acquired
TLR7 agonist resistance described by Bourquin et al. [16].8 Journal of Oncology
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Figure 6: 3M011 increases T-cell lymphocytic inﬁltration in RCC tumors. CD3 immunohistochemical staining of T-cell lymphocytes in
RENCA RCC xenografts following treatment with placebo or 3M011 imidazoquinoline. (a) Representative RCC tumor from a placebo-
treated mouse with mild T-cell lymphocyte collection at the tumor surface but little intratumoral penetration (200x magniﬁcation).
(b) Center of tumor from (a) with infrequent T-cell lymphocytes (200x magniﬁcation). (c) Example of a placebo-treated tumor with
moderate T-cell concentration at the tumor periphery but still little central tumor inﬁltration (100x magniﬁcation). (d), (e) Representative
3M011-treated tumors with large T-cell aggregates at the tumor edge (100x and 200x magniﬁcation, resp.); the bottom aspect of (d)
represents necrotic tumor. Note the eﬀective intratumoral penetration in (e). (f) Representative 3M011-treated tumor center showing
diﬀuse inﬁltration of CD3-positive T-cell lymphocytes (200x magniﬁcation). (g), (h) Tumor capsular CD3 staining (i) and intratumoral
CD3 staining (j) comparison in mice treated with placebo versus 3M011 on day 0 and day 7. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.005, and
†P = 0.52.
These authors demonstrated that a single injection of imi-
dazoquinoline induced tolerance to repeat dosing, associated
with suppression of proinﬂammatory cytokine production.
TLR7 tolerance lasted up to 5 days in their study, suggesting
awiderdosingintervalasusedinthisstudymaybenecessary.
With regards to drug toxicity, intratumoral injection
of imidazoquinoline was well tolerated by mice in this
study and appears to have therapeutic eﬃcacy against RCC
below doses needed for systemic toxicity. The dose used
here (2.5mg/kg) is lower than doses commonly studied
for imidazoquinolines in other cancer models (≥5mg/kg)
and subcutaneous doses reported to cause systemic toxic-
ity (≥10mg/kg) [32]. The most commonly reported sys-
temic side eﬀect of TLR7 agonists is anorexia [33], and
imidazoquinoline-treated mice in this study maintained
their weights well. TLR7 agonists in mice have additionally
been documented to cause “cytokine syndrome,” mani-
fested as shivering, and raised fur due to elevated systemicJournal of Oncology 9
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Figure 7: 3M011 increases proinﬂammatory cytokine production in mouse RCC tumors but not in mouse serum. (a)–(d) Levels of
intratumoral IL-6 (a), (b) and MCP-1 (c), (d) cytokines in mouse RCC xenografts on day 9 following treatment with placebo versus 3M011
imidazoquinoline on day 0 and day 7. (e), (f) Levels of serum MCP-1 in mice at the same time points. (b), (d), and (f) Compare mice
receiving placebo on both day 0 and day 7 versus mice receiving 3M011 on one or both of these days. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.005,
and †∗P = 0.08, †P>0.10. Error bars = standard error of the mean.
cytokines [32].Thissyndromewasnotobservedinourstudy,
and no increase in serum proinﬂammatory cytokine levels
could be detected after imidazoquinoline treatment despite
the increased intratumoral levels.
The molecular and cellular events responsible for imida-
zoquinoline-mediated tumor suppression, including the role
of the immune system, are not well characterized. While the
ability of imidazoquinolines to directly induce tumor cell
apoptosis likely plays a role, it is generally believed that the
clinical anticancer activity is mediated primarily by activa-
tion of a robust anticancer immune response resulting from
potent dendritic cell activation [34]. In the current study,
we found a signiﬁcant increase in cell death via apoptosis
in imidazoquinoline-treated tumors relative to controls, but10 Journal of Oncology
without change in viable tumor cell proliferation, support-
ing induction of apoptosis as the primary mechanism of
RCC tumor growth inhibition. This ﬁnding is consistent
with prior reports from our group, and others showing
imidazoquinolines may induce apoptosis in multiple cancer
types, including in the absence of immune cells [23, 31].
In addition, we found that imidazoquinoline treatment dra-
matically enhances T-cell lymphocyte inﬁltration along the
periphery and within the central bulk of RCC tumors, as well
as intratumoral production of proinﬂammatory cytokines,
consistent with upstream dendritic cell activation. Whether
this immune response contributes to the tumor growth sup-
pression observed in this study requires further study. While
we observed rapid timing of tumor suppression consistent
with an innate immune response, imidazoquinolines may
additionally exert antitumor activity by adaptive immune
systemactivation.Forexample,Redondoandcolleagueshave
shown in a melanoma mouse model that imidazoquinoline
pretreatment combined with tumor cryoablation to enhance
antigen presentation can prevent tumorigenesis of cancer
cellsreintroducedinto miceweekslater,supporting arolefor
memory T cells [35].
Lack of tumor growth suppression with repeated 3M011
treatments was observed in a single mouse in this study.
Inclinicalneoplasias,imidazoquinolinetherapeuticresponse
has been associated with increased CD8+ T-cell lymphocyte
tumor inﬁltration [36]. Consistent with this observation,
the nonresponsive mouse in our study demonstrated less
T-cell tumor inﬁltration than responsive mice. Clinical
resistance to imidazoquinoline has also been correlated with
increased intratumoral levels of immunosuppressive Treg
cellscharacterizedbytheCD4+/FOXP3+/CD25+ phenotype
which are believed to promote immunoevasion by inhibiting
cytotoxic T-cell responses [37–39]. Recent investigation in
mouse models has shown that imidazoquinoline therapy
increasesthenumberandactivityofTreg cellsinpartthrough
Treg expression of TLR7; however, opposite ﬁndings are
reported in cervical cancer patients [40–42]. Imidazoquino-
line responsiveness may thus depend on a complex balance
betweenopposingactivitiesofcytotoxicTcellsandimmuno-
suppressive Treg cells. Subtype characterization of inﬁltrating
T-celllymphocytesinimidazoquinoline-treatedRCCtumors
will be useful to elucidate the role of the immune system
and perhaps enable more accurate prediction of therapeutic
response.
In conclusion, this study demonstrates imidazoquinoline
TLR7 agonist to be an eﬀective therapy against estab-
lished murine RCC primary tumors. Similar to its well-
characterized eﬀects in dermatologic malignancies, imida-
zoquinoline treatment enhances RCC intratumoral T-cell
lymphocytic inﬁltration and proinﬂammatory cytokine pro-
duction while inhibiting RCC tumor growth via induction
of cancer cell apoptosis. These eﬀects may relate to the
ability of imidazoquinolines to stimulate potent dendritic
cell activation via TLR7 stimulation leading to a a down-
stream cytotoxic T-cell lymphocyte immune response. These
ﬁndings corroborate our previous demonstration of biologic
eﬃcacy against disseminated RCC cells and warrant further
investigation to determine whether TLR7 activation may
have clinical utility in therapeutically targeting both the
primary tumor and systemic disease in RCC patients.
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